title: Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study.
abstract: The aim of this study was to assess the efficacy and toxicity of an idarubicin-prednimustine combination in advanced breast cancer. 19 patients received idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days. Three objective responses with a median duration of 7 months were observed. Tolerance was good. A further 23 patients were given idarubicin administered at 15 mg/m2 days 1, 2 and 3 and prednimustine at the aforementioned dosage. 8 (35%) showed an objective response (4 CRs, 4 PRs) with a median duration of 6 months. No severe toxicity was observed. Results suggest activity of idarubicin-prednimustine combinations in advanced breast cancer, and further studies are indicated since this regimen is easily administered, especially to elderly patients.
authors.affiliation: Department of Medical Oncology, Hospital Germans Trias y Pujol, Badalona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Barnadas
authors.forename: C
authors.initials: C
authors.lastname: Mendiola
authors.forename: A
authors.initials: A
authors.lastname: Casado
authors.forename: A
authors.initials: A
authors.lastname: Villar
authors.forename: J
authors.initials: J
authors.lastname: Jimeno
authors.forename: M
authors.initials: M
authors.lastname: Clerigue
authors.forename: R
authors.initials: R
authors.lastname: Rosell
authors.forename: E
authors.initials: E
authors.lastname: Diaz-Rubio
authors.forename: H
authors.initials: H
authors.lastname: Cortés-Funes
authors.forename: M
authors.initials: M
authors.lastname: García de Paredes
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D011238:Prednimustine; D015255:Idarubicin